2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

PA infection

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Inhibitory Antibodies

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99649
    Gremubamab

    MEDI3902

    		 Bacterial Infection
    Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections .
    Gremubamab
  • HY-N0842
    Bevirimat
    1 Publications Verification

    PA-457; MPC-4326; YK FH312

    		 Virus Protease Infection
    Bevirimat (PA-457, MPC-4326, YK FH312) is an inhibitor of HIV-1 viral particle maturation.Bevirimat specifically inhibits the final rate-limiting step in Gag processing, preventing the release of the mature capsid protein (CA) from its precursor (CA-SP1), resulting in the production of immature non-infectious viral particles. Bevirimat can be used in HIV-1 infection studies .
    Bevirimat
  • HY-128780B
    SPR206 acetate
    1 Publications Verification

    		 Bacterial Antibiotic Infection
    SPR206 acetate is a polymyxin analog with antibiotic activity against Gram-negative pathogens, including multidrug-resistant (MDR) variants. SPR206 acetate has an anti-bacterial infection effect by interacting with the bacterium’s outer membrane. The MIC values of SPR206 acetate against Pseudomonas aeruginosa Pa14 and Acinetobacter baumannii NCTC13301 are both 0.125 mg/L .
    SPR206 acetate
  • HY-W157376
    PAMAM Dendrimer G0.0 amine (20% in methanol)

    		Bacterial Antibiotic Drug Intermediate Infection Cancer
    PAMAM Dendrimer G0.0 amine is a pore-forming channel antagonist, including anthrax toxin protective antigen 63 (PA63, IC50 = 231 nM) and C. botulinum C2 toxin subunit (C2IIa, IC50 = 940 nM). At concentrations of 10 and 20 µM, PAMAM Dendrimer G0.0 amine reduces C2 toxin-induced death in HeLa cells. Additionally, PAMAM Dendrimer G0.0 amine is a chelator of nickel. In complexes with polysulfone membrane-bound chitosan, PAMAM Dendrimer G0.0 amine selectively captures and stores carbon dioxide (CO2) in a gas-feed system. PAMAM Dendrimer G0.0 amine has been used in the synthesis of PAMAM Dendrimer G0.5 Carboxylate (CAS 339334-01-9) and PAMAM Dendrimer G1.0 Amine (CAS 142986-44-5). PAMAM Dendrimer G0.0 amine can be used in research related to infections, cancer, and drug delivery systems .
    PAMAM Dendrimer G0.0 amine (20% in methanol)
  • HY-157045
    ATP Synthesis-IN-1

    		ATP Synthase Infection
    ATP Synthesis-IN-1 (Compound 4), quinoline derivative, is a potent inhibitor of PA ATP synthesis activity. ATP Synthesis-IN-1 has PA ATP synthesis inhibition with IC50 value of 11.1μg/mL. ATP Synthesis-IN-1 also has antibacterial activity. ATP Synthesis-IN-1 can be used for the research of drug-resistant PA infection .
    ATP Synthesis-IN-1
  • HY-N0842R
    Bevirimat (Standard)

    PA-457 (Standard); MPC-4326 (Standard); YK FH312 (Standard)

    		 Virus Protease Infection
    Bevirimat (Standard) is the analytical standard of Bevirimat. This product is intended for research and analytical applications. Bevirimat (PA-457, MPC-4326, YK FH312) is an inhibitor of HIV-1 viral particle maturation.Bevirimat specifically inhibits the final rate-limiting step in Gag processing, preventing the release of the mature capsid protein (CA) from its precursor (CA-SP1), resulting in the production of immature non-infectious viral particles. Bevirimat can be used in HIV-1 infection studies[1][2][3][4].
    Bevirimat (Standard)
  • HY-173270
    Antibacterial synergist 3

    		Bacterial Infection
    Antibacterial synergist 3 is a dual-acting inhibitor of biofilm (IC50 of PAO1: 0.40 μM and IC50 of PA14: 1.45 μM). Antibacterial synergist 3 reduces virulence production by inhibiting the quorum sensing (QS) system and induces iron deficiency in P. aeruginosa PAO1. Antibacterial synergist 3 enhances the efficacy of Tobramycin (HY-B0441) and Ciprofloxacin (HY-B0356) in a mouse wound infection model. Antibacterial synergist 3 can be used for the research of P. aeruginosa infections .
    Antibacterial synergist 3
  • HY-B0693A
    Ranitidine bismuth citrate

    		Histamine Receptor SARS-CoV Bacterial Infection Metabolic Disease Cancer
    Ranitidine bismuth citrate is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine bismuth citrate antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA2 values of 7.2 and 6.95, respectively. Ranitidine bismuth citrate has selectivity for SARS-CoV-2-infected cells. Ranitidine bismuth citrate also has anti-Helicobacter pylori infection. Ranitidine bismuth citrate inhibits breast tumor development and spread in mice .
    Ranitidine bismuth citrate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: